Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Jul 23, 2026)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed July 23, 2026
Period End
July 23, 2026
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Leadership change8-K · Sep ’25Sep ’25

01—Abstract

Summary

Summary of the 8-K filed July 23, 2026. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (NYSE: WST) reported second-quarter 2026 results on July 23, 2026, with net sales of $872.3 milliona, up 13.8% reported and 12.7% organic.

Diluted EPS was $2.15b, up 18.1%, and adjusted-diluted EPS was $2.37, up 28.8%. Growth was led by the Proprietary Products segment, which posted net sales of $722.6 million (up 16.6%), with HVP Components sales of $424.1 million (up 19.4%) and HVP Delivery Devices sales of $131.2 million (up 29.6%). West Vantage net sales were $149.7 million, up 2.0%.

Operating profit was $179.1 millionc, and adjusted operating profit margin was 22.6%. The company raised its full-year 2026 guidance. Net sales are now expected at $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350 billion, and adjusted-diluted EPS is now expected at $8.85 to $9.05, up from $8.40 to $8.75.

Third-quarter 2026 net sales guidance is $820 million to $835 milliond, and adjusted-diluted EPS guidance is $2.14 to $2.24. The guidance excludes SmartDose 3.5mL sales, which are being sold to AbbVie. The release also notes a cybersecurity incident from May 2026 that the company said pressured West Vantage gross margins.

Cash flow was weaker than in the prior year. Operating cash flow for the first six months was $213.9 million, compared with $306.5 million, and free cash flow was $128.0 million. The company repurchased 1.8 million shares for $454.3 million in the first half of 2026, and cash and cash equivalents fell to $435.8 million from $791.3 million at December 31, 2025.

02—Key points

Key Highlights

  1. Q2 2026 net sales of $872.3 million rose 13.8% reported and 12.7% organic, with the Proprietary Products segment up 16.6%.
  2. Adjusted-diluted EPS of $2.37 increased 28.8% year over year; reported diluted EPS of $2.15 increased 18.1%.
  3. Full-year 2026 guidance was raised: net sales to $3.345–$3.380 billion and adjusted-diluted EPS to $8.85–$9.05.
  4. Biologics-driven HVP Components sales of $424.1 million rose 19.4%, and HVP Delivery Devices rose 29.6% to $131.2 million.
  5. West Vantage gross margin was pressured by the May 2026 cybersecurity incident, with segment gross profit falling to $21.2 million from $25.6 million.
  6. Operating cash flow fell to $213.9 million for the first half of 2026 from $306.5 million, and free cash flow was $128.0 million.
  7. The company repurchased $454.3 million of shares in the first half of 2026 and declared a third-quarter dividend of $0.22 per share.

03—Questions

Frequently Asked Questions

  1. What drove West's second-quarter 2026 sales growth?

    Growth was driven mainly by the Proprietary Products segment, where net sales rose 16.6% to $722.6 million. Biologics sales rose 30.3% to $374.8 million, and the filing cites strength in NovaPure and FluroTec products and GLP-1 elastomers as contributors.

  2. Why did West raise its full-year 2026 guidance?

    Management said second-quarter net sales and adjusted EPS exceeded expectations, citing strong Biologics demand, a favorable mix shift toward HVP upgrades including Annex 1, and ongoing GLP-1 elastomer growth. Full-year net sales guidance rose to $3.345–$3.380 billion and adjusted-diluted EPS guidance rose to $8.85–$9.05.

  3. How did the cybersecurity incident affect West's results?

    The company said West Vantage gross margins came in below expectations because of the cyber incident from May 2026. The segment's gross profit margin was 14.2% in the quarter, and nonrecurring professional fees related to the incident are excluded from adjusted results.

  4. How is West's cash position and capital allocation changing?

    Cash and cash equivalents fell to $435.8 million at June 30, 2026, from $791.3 million at December 31, 2025. Share repurchases totaled $454.3 million in the first half of 2026, and the company's full-year capital expenditure guidance is unchanged at $250–$275 million.

  5. What is expected in the third quarter of 2026?

    Third-quarter net sales are guided to $820–$835 million, with reported growth of 1.9% to 3.8% and organic growth of 7.0% to 8.9%. Adjusted-diluted EPS is guided to $2.14–$2.24, and the guidance excludes SmartDose 3.5mL sales.

04—Continue

← View all 8-K filings